Dramatic reductions in mother-to-child HIV transmission (MTCT) have accompanied the rollout of Option B+ and test-and-treat strategies throughout the world, with MTCT now below 2% in some high prevalence regions of Africa where it was over 30% early in the epidemic. However, the past decade has also brought with it a better understanding of potential risks associated with 3-drug ART use in pregnancy. Evidence points to associations between ART use (particularly from before conception) and higher risk for adverse pregnancy outcomes, including stillbirths, preterm delivery, and low birth weight infants. Until recently there has been little data to compare individual ART exposures, but concerns have now emerged for increased risk with specific antiretroviral agents and combinations. This talk will review the current data for adverse pregnancy outcomes associated with specific ART regimens used in pregnancy. Mechanisms to explain these findings are lacking, and remain an urgent field of study. Ongoing surveillance for adverse pregnancy outcomes is warranted for women exposed to ART in pregnancy, particularly as new ART regimens become available.